Type of PPOs according to START criteria | Control Group N (%) | Intervention group N (%) |
---|---|---|
Cardiovascular System | ||
ā āVitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors in the presence of chronic atrial fibrillationā | 2 (0.8) | 7 (2.9) |
ā āAntiplatelet therapy with a documented history of coronary, cerebral or peripheral vascular diseaseā | 10 (4.2) | 5 (2.1) |
ā āStatin therapy with a documented history of coronary, cerebral or peripheral vascular diseaseā | 11 (4.6) | 11 (4.6) |
ā āAngiotensin Converting Enzyme (ACE) inhibitor with systolic heart failure and/or documented coronary artery diseaseā | 30 (12.5)* | 16 (6.7)* |
ā āBeta-blocker with ischaemic heart diseaseā | 22 (9.2) | 16 (6.7) |
āāAppropriate beta-blocker (bisoprolol, nebivolol, metoprolol or carvedilol) with stable systolic heart failureā | 6 (2.5) | 6 (2.5) |
Respiratory System | ||
ā āRegular inhaled Ć2 agonist or antimuscarinic bronchodilator mild to moderate asthma or COPDā | 11 (4.6) | 17 (7.1) |
ā āRegular inhaled corticosteroid for moderate-severe asthma or COPDā | 10 (4.2) | 6 (2.5) |
Musculoskeletal System | ||
ā āVitamin D supplements in older people who are housebound or experiencing falls or with osteopeniaā | 37 (15.4)** | 14 (5.8)** |
ā āXanthine-oxidase inhibitors with a history of recurrent episodes of goutā | 2 (0.8) | 3 (1.3) |
Endocrine System | ||
ā āACE inhibitor or Angiotensin Receptor Blocker (if intolerant of ACE inhibitor) in diabetes with evidence of renal diseaseā | 20 (8.3) | 29 (12.1) |
Urogenital System | ||
ā āAlpha-1 receptor blocker with symptomatic prostatism, where prostatectomy is not considered necessaryā | 9 (3.8) | 6 (2.5) |
ā ā5-alpha-reductase inhibitor with symptomatic prostatism, where prostatectomy is not considered necessaryā | 12 (5.0) | 9 (3.8) |